{"name":"Chongqing Precision Biotech Co., Ltd","slug":"chongqing-precision-biotech-co-ltd","ticker":"","exchange":"","domain":"chongqingprecision.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"Anti-CD5 CAR NK cells","genericName":"Anti-CD5 CAR NK cells","slug":"anti-cd5-car-nk-cells","indication":"Relapsed or refractory B-cell malignancies","status":"phase_1"},{"name":"C-4-29 Cells","genericName":"C-4-29 Cells","slug":"c-4-29-cells","indication":"Other","status":"phase_1"},{"name":"CD19-targetd CAR-T","genericName":"CD19-targetd CAR-T","slug":"cd19-targetd-car-t","indication":"Other","status":"phase_1"},{"name":"PTOC1","genericName":"PTOC1","slug":"ptoc1","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Anti-CD123 CAR NK cells","genericName":"Anti-CD123 CAR NK cells","slug":"anti-cd123-car-nk-cells","indication":"Acute myeloid leukemia","status":"phase_1"},{"name":"BCMA CAR-T cells","genericName":"BCMA CAR-T cells","slug":"bcma-car-t-cells","indication":"Multiple myeloma","status":"phase_2"}]}],"pipeline":[{"name":"Anti-CD123 CAR NK cells","genericName":"Anti-CD123 CAR NK cells","slug":"anti-cd123-car-nk-cells","phase":"phase_1","mechanism":"CAR-T cell therapy targeting CD123","indications":["Acute myeloid leukemia"],"catalyst":""},{"name":"Anti-CD5 CAR NK cells","genericName":"Anti-CD5 CAR NK cells","slug":"anti-cd5-car-nk-cells","phase":"phase_1","mechanism":"Anti-CD5 CAR T cells target and kill cancer cells by binding to the CD5 receptor on their surface.","indications":["Relapsed or refractory B-cell malignancies"],"catalyst":""},{"name":"BCMA CAR-T cells","genericName":"BCMA CAR-T cells","slug":"bcma-car-t-cells","phase":"phase_2","mechanism":"BCMA-targeting CAR-T cells","indications":["Multiple myeloma"],"catalyst":""},{"name":"C-4-29 Cells","genericName":"C-4-29 Cells","slug":"c-4-29-cells","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"CD19-targetd CAR-T","genericName":"CD19-targetd CAR-T","slug":"cd19-targetd-car-t","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"PTOC1","genericName":"PTOC1","slug":"ptoc1","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxOS1d5X2ZDZnQ4dUxnSGdKN0lWTjdHX2JzWWdKMk1vSmczWER5XzVHM0VJX2dpVFBEUk1aYldlQkVwSlZCMHl5UUlUQU15U1ZObUtvLW5JNWVLN1VBZEZtNVB6NWZNQU9yVk5obnpPN3dsQlJMcmItaHFoM29pSVhaeFpSbEFyZjdwSUt2OTNlcHY1eXBxaHFxTFZqMjhfMkktUVhweFZpWktGWW9tclBmT0ZacFhKODlVcVMtd3VZQ09LSVFjM2FfcTlreWlHYjdac1p5czJQRC0zbzZ6Ty1aRW9MWEpHSzhBNlBvZks0d3BQbmV4WFE?oc=5","date":"2026-03-24","type":"pipeline","source":"Barchart.com","summary":"Metastatic Renal Cell Carcinoma Treatment Pipeline Shows Strong Momentum as 40+ Pharma Companies in the Race | DelveInsight - Barchart.com","headline":"Metastatic Renal Cell Carcinoma Treatment Pipeline Shows Strong Momentum as 40+ Pharma Companies in the Race | DelveInsi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAJBVV95cUxORHIxUlJaY2NsZGZBc0JyYVBMLXZHdGFfa19VZ05lTkxna3RMYjZnSEZudnVuWVRrUUM0R3phUmgydGprYjNYMkw2TXk2UXlfY1VRY3ptTjgtZ0NOT09NTkdvaV9ySGhxRWgxSGRPTTRYeGZJcUprVXBOdHFTeHZEMnBaSk1tRHl0QmtwNEtIekJpMnlKb3Y5UkxiT3ZZV2RnY1ExalNjQXVlT2JHblBVNjR0RWU4MEZtUG1FcHJ2VTRKSkkxVnVBbXlSQV9EdmNIQm9TSzE2eWF0NDFPM2l4eGFjdUQ3Uk5WRVBIRVExWmpSNXI2TG5jaGtUS1J3R28zektDbWZkS3VudTJSQ2d2MA?oc=5","date":"2026-02-12","type":"pipeline","source":"PR Newswire","summary":"BCL-2 Inhibitors Market Poised for Robust Growth During the Forecast Period (2025-2034) as Oncology Pipelines Expand | DelveInsight - PR Newswire","headline":"BCL-2 Inhibitors Market Poised for Robust Growth During the Forecast Period (2025-2034) as Oncology Pipelines Expand | D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxNdGJiX1hIRnBfajZ4OUVpTXN3X1RHTUNnT1RLdUFOSGlGbHN5NjVnbll1a1h4UEVpNjNHcURnUF9xb1pVM2pwX2JVVFlnWHh6SU9LOFh3U0Zwd1FXZmxpVXpvbHZtcGRhTU14YmxudmF3azRzckJlYUpvZ2dlN2NJbTFPYkdIaTFLVHhOTTZBZWRSNlB5LTQ5UnJOeHlGeUpaVTkwNERUYi02blpuUHhPdjhBZ3p6NTRLTlNLdFZ5Slh6YVlCblhXTGdzYjNEMHMwY0ZwZDV0MDBoU3p5V1RQTnpHb1I1NUJmTGotckNWZzQwSFdTVUdYaFc4S29yWWc5Q1pnTTZib1VxLTRHSmUzbUprc0c1OEdpN2JtZzd1MUxLMm1SNDhjMERR?oc=5","date":"2025-07-07","type":"trial","source":"globenewswire.com","summary":"Bispecific Antibody Clinical Trial Pipeline Gains Momentum: - globenewswire.com","headline":"Bispecific Antibody Clinical Trial Pipeline Gains Momentum:","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxNOXcyek5vakItWXNwTWFOdFM3OEhGZmJieFYxLWl4dDRmNnlaNGN4cXZxM2VyRjMzUnBKa1dobmdmbnZIekUxR2F5eFpiQmRicGcwTlMyUVN3Zkk4aHBFYWM0ZnZnNUg0XzZTNktyeFQ1SUw3cmx0VldjdjhGeUwzNk5FNlVFekUxb0cxdUNrUVBaS3FLc1Ixa0lIZmRqRG83VlpPdWlBVk9fN1NhZzBFMlgzWkQxN01hMkhfM094d3hWSG9nOW1BMFlJQUk2TlJjbjZiN1U2NXhEU19HdXRveDNNdGp0S08yRlUzVDZNQ1VQUHpONmNNazhtcjI?oc=5","date":"2025-03-24","type":"pipeline","source":"PR Newswire","summary":"CARVYKTI Continued Performance Reflects Growing Confidence in CAR-T Therapies for Multiple Myeloma | DelveInsight - PR Newswire","headline":"CARVYKTI Continued Performance Reflects Growing Confidence in CAR-T Therapies for Multiple Myeloma | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxQRFd2RXZjNndLOGdHTkZybUwzbTg5NzduNkhOVlo5TjFmbmpRSmZtZzJXWjA5X0F5a1lqNFAxM3JYV1BfOUNJakluR3E0d0xGamF5ZlIyNWV1RmhEVUo2M054Z3haR2tCNHY5eWhJRlpRR190dVV4aFJMaldFdkxQZ0dwa2loZ0g4ZXBwT1pkdUE2REtfYl9YNW8tOXM3eEpBNGhZVHpJN2Q4cnVUMmhVOXUtVTN3ak1fNWxkcHZ3QlBjUmlWbml2RG5ENElJNjVWRERmT3pUaTNFMkwyV0JoeEo1MFVZc1hRc0xqVG85QQ?oc=5","date":"2025-03-20","type":"pipeline","source":"PR Newswire","summary":"DARZALEX Continues to Redefine Multiple Myeloma Treatment with Robust Market Performance | DelveInsight - PR Newswire","headline":"DARZALEX Continues to Redefine Multiple Myeloma Treatment with Robust Market Performance | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxQV1JBcWNmYk85cFJyVU9PYzE1c0x3b2RjcW9fN1JUQ1FNc1BRUjNMRkltMTl3cHZCdnpoOHFvQlFCY3BrQ0ZWa1lxQnNCb055NlZyVlcwelZGd1hxRmhCVnBybXdSS1B3eFJZT1JUV0JfWGFEM2Vvc3ZJNzdRdUlPcmR4YkJjSEEyWGhIYm0xZkk0cXJLTzNXeXR3anY5cjA4eEQwbzNVWjUtSWxDdm55Ti0zWFh3TW8zUnlRcmpVTFhQc0NCMmJydTdVUzBYbXdGbGR5R2xPeWNLX3VuV0t6bWduNW1GYnhSYl8zbmFfa2lteDBGTzNtQUlKNHlOczZjYXFISHdpc3dtUm9IY0FCNmQwZ2hPeEhYdTAwaFFwTXlGd2Z4NHdpbUxiZXU1dGM5UjBrVjQ2UTc5QlJkM0NyUVlQWnBQTkU?oc=5","date":"2025-03-05","type":"trial","source":"globenewswire.com","summary":"CAR T-cell Therapy Clinical Trial Pipeline Experiences - globenewswire.com","headline":"CAR T-cell Therapy Clinical Trial Pipeline Experiences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxNcThTYnBTaFZXUXdNYzlhY0ZBdUlXNzE4cnVhSzlCVFF1T0JEeG9odldXSWtaYkQ4UmlCbzJrVVFsVWZMc0x5d1UxZkRXeUhsNTNnYkUySHNOOTZGZzVCYkNhMlBPRm1rUWpVNU9VUGhuRTlQQms4TnlpVnJEd0QyeENydmtnZkRNdmNDT0FIN3dvMVJ5SXNfS1pTTnBFWW53Y0RTazN6a2tQRXQ4ZnQwN0luYm9HTkxydE1EVVpWeS0zam9NRXp1UHlETlBkUWxYUmJIcTRvQkpyQVRLVjdIVWlqZ2U2dUtYbXVqUnhXamZVWlVSM25jT0tjX1Y0SC13dWNB?oc=5","date":"2025-03-05","type":"pipeline","source":"PR Newswire","summary":"XPOVIO Continues to Disrupt the Oncology Market with Expanded Indications and Strong Market Performance | DelveInsight - PR Newswire","headline":"XPOVIO Continues to Disrupt the Oncology Market with Expanded Indications and Strong Market Performance | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAJBVV95cUxQVGhLNGF1QzFjZ2Y2dG8zLXBVSVZoaENDTWFFeW9nZ0otZmRYNHZqWlZ4U1FjNm5BazBURzlwc1IyWmJEcHoxcjRYdHV6V1pENDVDUXc2WENJV3FYNHVibmhpZEJGTkNaOWRpbDNVSmdRMzBXSEl6MmI3R0dfQ0VORnptSDdHSTVfMWpuM25hc3JZQTVuNnhidlRaZFpTZmE5U2RoWE5XMllIQlk1Z1RhVkJHV3B4a1ZGUWxmZGxhN2hpR2RNQkRsZ2JWZjNQTHBKLU1hMy00a0NndHlOb215OE9NZ1U5WklzWnVaZXJZVTNDZWM2Z0hYZDhWdThaUVp6ZG9CbldRSkZDTXc2R3ZnRFd3TDlkZ3ZPaDVtLXJxWlFySG1ZUjA4d2dRVjNOdlVLU1V1Vg?oc=5","date":"2024-09-24","type":"trial","source":"globenewswire.com","summary":"Renal Cancer Clinical Trial Pipeline Appears Robust With - globenewswire.com","headline":"Renal Cancer Clinical Trial Pipeline Appears Robust With","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQZUxKUEg5OVdyclNkSjJhRENXeWlJOElSb19EeVJPeDFuZDl0MWprYkh1ck1Wb0g1SUVsVkN6RDlORldaWHFmeDNiMWoycU1UTjlvMFlaMlZJS1E4d0JtT3lDcW52YTZiNXBSY0VxNW5BZ1lzQ2E1VXpTaVpEeDVIYlhIWUhXTzkzYURsWWc1LTM?oc=5","date":"2024-06-27","type":"trial","source":"Clinical Trials Arena","summary":"CAR T cells in lupus: Promising results at EULAR 2024 and emergence of China - Clinical Trials Arena","headline":"CAR T cells in lupus: Promising results at EULAR 2024 and emergence of China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTFByaHdhaURCaDZ1ZkVMOEZILXhjajV5T2VWYzNMRXF0bVNjUTJjaVl3cjdPZTFiT0M2QlQzbnROUGpwX2p1cTRueFEtMnlZamNvY0Z6aU4xV3BTTHNrYWRUTDdJRGN2eTgtZkV6WG43OA?oc=5","date":"2024-04-02","type":"pipeline","source":"Wiley Online Library","summary":"CAR‐T‐cell products in solid tumors: Progress, challenges, and strategies - Qian - 2024 - Interdisciplinary Medicine - Wiley Online Library","headline":"CAR‐T‐cell products in solid tumors: Progress, challenges, and strategies - Qian - 2024 - Interdisciplinary Medicine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPa2RuNF9TUkZmdHRsRXZCUmNrZkRFbnlVTm1uX2FscU5sY0VjR1ptalFwMlBXZHpZdlBRQTFXUGpmV3g1X0RZcl9qQmxPMmQ2Q2VkMWEwVFZBVTZBdG5BbW5hYmxiWTNzMDBCdUVWZV9HUVJrajVYM0VwSWZmUlhlMU5mallVeTZzQ1Q1Y3pveUt1UVAtLS1B?oc=5","date":"2024-01-01","type":"trial","source":"Yahoo Finance","summary":"Propulsion of Small Lymphocytic Lymphoma Clinical Trial Pipeline as Novel and Extensive 80+ Therapies Likely to Enter in the Domain | DelveInsight - Yahoo Finance","headline":"Propulsion of Small Lymphocytic Lymphoma Clinical Trial Pipeline as Novel and Extensive 80+ Therapies Likely to Enter in","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxPQVdzNTI2dmMtX2hFQlB1aGpqTWNoUDY2R0dzLXpuQVV1ZWdNTERzTzNtVUVkc01HVDJyYWQzYUlvUVVqM0pBV0FmOHBKeUg0LW9qM3hPQ1dLYzVjVlJIN3NoOFJkLVU4WElrS05uMGF0bTBvSUZ4R3RNcGl6LXVEYU0wUEhmc0JMRW9QcUN3S0FBbXBmSzl1WmxIUHFzN3NpakM0YWlidVZTRWNNQ3RQd01YR3lXTnplTU9ZQ0hJTjRtdWFJS1M1cnNDb0Yta2dzcDB1bFhGRlpsZldMN2FWMUNiQjh0aTU3YXpvY1NsMA?oc=5","date":"2023-11-08","type":"regulatory","source":"CRISPR Medicine News","summary":"Press Release Service: CD19-Targeting Therapies Show Remarkable Growth, Revolutionizing Cancer Treatment with High Response Rates - ResearchAndMarkets.com - CRISPR Medicine News","headline":"Press Release Service: CD19-Targeting Therapies Show Remarkable Growth, Revolutionizing Cancer Treatment with High Respo","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_1":5,"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}